



GSK Hamilton Site Overview

Debbie Lennon
Site Director

GSK: A leading biopharma company

GSK: a focused biopharma company, with expertise in developing innovative specialty medicines and vaccines.

Leading portfolio of vaccines, specialty and general medicines.

Almost 70,000 people and a presence in more than 75 countries worldwide.

Innovation powered by £6.4 billion R&D investment in 2024.

- 71 medicines and vaccines in development.
 - 19 assets in phase III / registration
 - 5 major product approvals expected in 2025 – 3 currently approved as of OCT2025
-



Our portfolio

Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems. Alongside current growth drivers, our R&D is focused on 14 scale opportunities launching between 2025 and 2031.

Specialty Medicines

Our portfolio of specialty medicines prevents and treats diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer.

1st

to pioneer HIV treatments in 1980 and leaders in HIV innovation

50 years

helping millions of people with respiratory conditions to breathe more easily

80%

of our revenue growth in 2024 generated by specialty medicines

Vaccines

Our broad vaccines portfolio targets infectious disease at every stage of life, helping to protect people from meningitis, shingles, RSV, flu, polio and many more.

20+

vaccines in our portfolio

>1m

vaccine doses delivered each day

General Medicines

From antibiotics to inhaled medicines for asthma and COPD, we have a broad portfolio of general medicine products, many of them market leaders, making life better for millions of people worldwide.

100+

countries are supplied with GSK products

#1

Trelegy remains number one brand in COPD and asthma globally

GSK

Getting ahead of disease in four core therapeutic areas

With focused R&D investment in specialty medicines and vaccines

Respiratory, immunology and inflammation

We have a deep understanding of the underlying drivers of disease in different groups of patients with conditions like asthma and COPD. Our ambition is to redefine the future of respiratory medicine with a broad portfolio of next-generation, long-acting treatments that work in distinct ways to help as many people as possible.

We're building on our decades of knowledge in inflammatory mechanisms to target fibrotic lung, liver and kidney disease.

Oncology

Cancer remains a leading cause of death with unmet patient need.

Our ambition is to help increase overall quality of life, maximize survival and change the course of disease, expanding from our current focus on blood and gynecologic cancers into lung and gastrointestinal cancers, as well as other solid tumors.

Our research uses precision medicine-based technology to match the right treatment to the right patient.

HIV

HIV is one of the world's biggest health threats and our goal is to minimise the impact of HIV on people's lives by treating, preventing and ultimately curing it.

For decades, we've transformed the lives of people living with HIV by making breakthroughs in treatment and prevention. Our work in HIV is led by ViiV Healthcare, which we majority-own, with Pfizer and Shionogi as shareholders. ViiV Healthcare is the only company exclusively dedicated to treating and preventing HIV with an ambition to end the HIV epidemic.

Infectious diseases

Infectious diseases affect everyone, everywhere, putting a major strain on societies and healthcare systems. Our combined expertise in medicines and vaccines means we can focus on both prevention and treatment of infectious diseases.

Our priorities include seasonal infections, chronic infections, common childhood diseases and rarer but critical conditions like meningitis. We also focus on bacterial infections where resistance is creating an urgent need for new treatments.

GSK Future Investments



01 October 2025

GSK to invest \$30 billion in R&D and Manufacturing in the United States over next 5 years



US Investment

\$30bn in R&D and manufacturing over the next 5 years, including a new \$1.2bn investment in manufacturing

New flex factory

Includes a new biologics flex factory in Upper Merion to produce best-in-class respiratory and cancer medicine

\$1.2bn in manufacturing

To strengthen capability to deliver new medicines and vaccines, accelerate AI and advanced digital technologies

GSK's pivotal role

Alongside other investments made across the network, GSK's recently announced investments in the United States recognizes GSK's Global Supply Chain's role in pipeline delivery and new product launches.

GSK Hamilton Montana



01 October 2023


Hamilton Site



Facility is located on a 35-acre campus (236,000 square foot operation)

What is MPL?

- MPL is Monophosphoryl Lipid A
- MPL is derived from a bacterial cell wall component known as lipopolysaccharide (LPS). LPS is a highly potent stimulator of the immune system.
- LPS is on the outside of the bacteria, therefore, it is highly “visible” to the immune system.



Definition of **adjuvant** (ad·ju·vant):


A substance that enhances the body's immune response to an antigen.

Why is MPL Important?

MPL is a powerful **Vaccine Adjuvant** which improves the effectiveness of our vaccines by doing one or more the following:


- 1) Increases the strength and duration of the immune response.
- 2) Shortens the time required for protective immunity.
- 3) Reduces the antigen dose required for protective immunity.
- 4) Increases the level of cross-protection.

MPL is a key component in GSK's Innovative Adjuvant Systems. It is combined with QS-21 to create the AS01 Adjuvant System used in several important vaccines.



What is QS-21?

- **QS-21** is a saponin extracted from the inner bark of the soap bark tree: *Quillaja Saponaria Molina*.
- **QS-21** is one of several saponins present in the extract, it's isolated from that mixture using chromatography and supplied as a freeze-dried powder.
- Just like MPL, it is a potent **Vaccine Adjuvant**. When combined with MPL, there is a synergy between the two components, increasing the immuno-stimulation that would be activated by each immuno-enhancer alone.



QS-21 Molecule
MW=1988 Da

Definition of **adjuvant** (ad·ju·vant):

A substance that enhances the body's immune response to an antigen.

Why is QS-21 Important?



QS-21 is a powerful **Vaccine Adjuvant** which improves the effectiveness of our vaccines by doing one or more the following:

1. Increases the strength and duration of the immune response
2. Shortens the time required for protective immunity
3. Reduces the antigen dose required for protective immunity
4. Increases the level of cross-protection

QS-21 is a key component in GSK's Innovative Adjuvant Systems. It is combined with MPL to create the AS01 Adjuvant System used in several important vaccines.



GSK Hamilton

Our contribution...



>40M doses supplied to patients
44% of Vx sales in 2024

GSK


GSK Hamilton Economic Impact in Montana

State and local level

- Job creation
- Increased tax revenues
- Business growth through a global supply chain
- Overall contributions to economic development by attracting investment and enhancing community infrastructure



Number of Hamilton GSK Employees



GSK